EGFR and non-small cell lung carcinoma: The efficacy of EGFR-tyrosine kinase inhibitor (EGFR-TKI) for advanced EGFR-mutant NSCLC patients is well accepted, and current studies are exploring the application of EGFR-TKI in the adjuvant setting (12).